This Pharma Company Reports 25 per cent Profit Growth: Aiming for Rs 750 Crore Revenue by FY26, Promoter and FIIs Increased their Stake
The company has given returns of 46.23 per cent in a year.
Lincoln Pharmaceuticals Ltd announced its quarterly result for the June quarter where it reported a standalone net profit of Rs 23.67 crore in Q1 FY25.
In the Quarterly Results of the Q1FY25, the company reported a revenue of Rs 157.69 crore, which is a 10.03 per cent increase from June 2023. Net profit for the same period was Rs 23.67 crore, reflecting a 24.51 per cent rise compared to the previous year. For the fiscal year ending March 2024, the company achieved a revenue of Rs 614.97 crore, marking a 15.43 per cent growth from FY23. Net profit for FY24 was Rs 93.3 crore, up by 27.98 per cent from FY23.
Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "Company has delivered exceptional operational and financial results in the first quarter of the fiscal year 2025. Both domestic and export operations have shown robust growth. We are confident to enhance profitability and margins going forward while sustaining strong growth trajectory. With a pipeline of new product launches for both domestic and international markets, coupled with strategic expansion into new territories, the company aims to strengthen its market position and achieve its revenue target of Rs 750 crore by the end of the fiscal year 2026."
Lincoln's commitment to expanding its global footprint while meeting diverse healthcare needs. Going forward the company is focus is on enhancing offerings in lifestyle, chronic, women's healthcare, and dermatology, alongside the t existing acute care lineup. Lincoln showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.
Over the last 5 years, company has delivered over 13 per cent CAGR in profits and higher single digit growth in sales. The company has been successful in increasing its profit margins from around 13 per cent in FY 19 to over 16 per cent in FY24. Company is also ranked among a very few companies to achieve a profit growth every single year from FY13 to FY23. It is among only 16 companies out of 4,200 plus listed companies in the Indian stock exchange to do so as per the analysis of Morningstar.
Lincoln exports to 60+ countries spanning East & West Africa, Central & North America, Latin America, and Southeast Asia. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion, while also aggressively pursuing product registration for its Cephalosporin plant in Mehsana. These initiatives align with the company's revenue target of Rs 750 crore for FY26.
Lincoln Pharmaceuticals Ltd has a market capitalisation of Rs 1,313 crore and is currently trading at Rs 651. The stock has a 52-week high of Rs 755 and a low of Rs 450. Its price-to-earnings ratio is 13.4, the book value is Rs 296, and the dividend yield stands at 0.23 per cent.
Investors must keep this Small-Cap stock on their radar.
Disclaimer: The article is for informational purposes only and not investment advice.